Sunday, October 19, 2014

Emergency Aeromedical Evacuation Services

Emergency Aeromedical Evacuation Services

Solicitation Number: SAQMMA14C0155
Agency: Department of State
Office: Office of Acquisitions
Location: INL Support
  • Print
:
SAQMMA14C0155
:
Justification and Approval (J&A)
:
FAR 6.302-2 - Unusual and compelling urgency
:
August 18, 2014
:
SAQMMA14C0155
:
Added: Sep 03, 2014 2:13 pm
This requirement is in response to Department of State's diplomatic mission overseas to provide movement of emergency response personnel into and out of hazardous/non-permissive environments and medical evacuation of critically ill/injured patients, including those infected with unique and high contagious pathogens. This is an immediate response to the Ebola Virus Crisis.
Please consult the list of document viewers if you cannot open a file.

J&A

Type:
Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Posted Date:
September 3, 2014
J&A_-_MEDEVAC_SVCS.pdf (2,023.46 Kb)
Description: J&A under "urgent and compelling" for Emergency Aero-medical Support Services
:
1038 South Patrick Drive
Patrick AFB, Florida 32925
United States
:
Anna M. Garcia,
Contracting Officer

Is CDC Hiding Enterovirus Link To Illegal Alien Kids?

Is CDC Hiding Enterovirus Link To Illegal Alien Kids?

 Posted 
Public Health: A disease that was once rare in the U.S. is killing Americans, and its rise coincides with the tidal wave of unaccompanied minor children arriving from Latin America under our de facto open-border policy.
Eli Waller, a 4-year-old New Jersey boy, died Sept. 25. He was reportedly fine and healthy when he went to bed but died overnight, with the cause confirmed by the Centers for Disease Control to be enterovirus D-68 (EV-D68), one more casualty in an epidemic that has swept the country seemingly out of nowhere.
The CDC website reports that from mid-August to Oct. 10, the CDC itself or state authorities confirmed that 691 people in 46 states and the District of Columbia had come down with some sort of respiratory illness caused by EV-D68. Five children, including Eli, died from their infections.
More than a few observers have noticed that the sudden increase in EV-D68 cases coincides with the rapid rise of unaccompanied minors crossing our porous border. These children, often without proper health screenings, have been distributed throughout the U.S.
The CDC denies any connection, noting that cases of EV-D68 have occurred in the U.S. for decades, having first been detected in California in 1962.
"There is no evidence that unaccompanied children brought EV-D68 into the United States, we are not aware of any of these children testing positive for the virus," the CDC told World Net Daily in an email response to an inquiry into the possible connection.
It is true that EV-D68 has been in the U.S. at least since 1962. But according to a study done by doctors from the Division of Viral Diseases at the National Center for Immunization and Respiratory Diseases published on the CDC's own website, EV-D68 "is one of the most rarely reported serotypes, with only 26 reports throughout the 36-year study period (1970 through 2006)."
There's often a disconnect between coincidence and correlation. But we suspect that the jump in cases from 26 in 36 years to nearly 700 in one year coming at the same time as the open-border influx of improperly screened illegal aliens is more than just a coincidence.
As the relentless investigative reporter Sharyl Attkisson points out, a 2013 study in Virology Journal found human enteroviruses, including EV-D68, present in 3% of nose and throat swab samples taken from children from Latin America under 8 years old with a median age of 3. Related human rhinoviruses were found in 16% of the samples, according to the study authored by a team of virologists headed by Josefina Garcia from U.S. Naval Medical Unit 6 in Lima, Peru.

A SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FOR SMALL BUSINESS INNOVATION RESEARCH (SBIR) CONTRACT PROPOSALS

A SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FOR SMALL BUSINESS INNOVATION RESEARCH (SBIR) CONTRACT PROPOSALS

Solicitation Number: PHS-2015-1
Agency: Department of Health and Human Services
Office: National Institutes of Health
Location: National Institute of Allergy and Infectious Diseases
  • Print
:
PHS-2015-1
:
Solicitation
:
Added: Jul 31, 2014 2:29 pm
1. National Institutes of Health, Bethesda, MD 20892 and Centers for Disease Control and Prevention, Atlanta, GA 30305 are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward meeting the program objectives of the agencies. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM SOLICITATION PHS 2015-1 with a closing date on or about November 5, 2014, for receipt of proposals, soon will be available electronically through the NIH Small Business Research Funding Opportunities (http://sbir.nih.gov) Web site and at fedbizopps.gov. The SBIR Phase I, Fast-Track, Direct to Phase II Contract Solicitation will be available ONLY via electronic means. Printed copies of the Solicitation will not be distributed. Potential offerors are encouraged to check the NIH Small Business Research Funding Opportunities Web site and fedbizopps.gov for updates on the program. Any updates or corrections to the Solicitation will be posted there. The purposes of the SBIR program are to: (a) stimulate technological innovation in the private sector; (b) strengthen the role of small business in meeting Federal research/research & development (R/R&D) needs; (c) increase the commercial application of Federally-supported research results; (d) foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns; and improve the return on investment from Federally-funded research for economic and social benefits to the Nation. For purposes of the SBIR program, a small business concern is any business concern that, on the date of award, (1) is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor; (2) is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture; (3) more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern AND (4) has, including its affiliates, no more than 500 employees. Following are the research topics identified in the NIH/CDC SBIR Contract Solicitation [PHS 2015-1]: NATIONAL INSTITUTES OF HEALTH (NIH) - NATIONAL CANCER INSTITUTE (NCI): Vacutubes to Preserve the Viability of Circulating Tumor Cells; Development of Advanced Culture Systems for Expansion of Cancer Stem Cells; Development of Novel Therapeutic Agents That Target Cancer Stem Cells; Cell-Free Nucleic Acid-Based Assay Development for Cancer Diagnosis; Predictive Biomarkers of Adverse Reactions to Radiation Treatment; Systemic Targeted Radionuclide Therapy For Cancer Treatment; Validation of Mobile Technologies for Clinical Assessment, Monitoring, and Intervention. NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS): Exploring the Potential of CRISPR/CAS Genome-editing Tools; Assay Development for High-Throughput Screening of Chemicals of Toxicological Concern; Simple and Robust Reaction Progress Analyzer; Online Real Time Metals Analysis at Low ppm Level. NATIONAL HEART, LUNG AND BLOOD INSTITUTE (NHLBI): Transcatheter Cerclage Mitral Annuloplasty (SBIR-TT); Closure Devices for Transcaval Access to the Abdominal Aorta; In-bore Defibrillation for Invasive MRI Cardiology Procedures; Devices to Close Ductus Arteriosus in Premature Infants; Therapeutic Delivery of ADP-ribosylarginine Hydrolase; Selective Silencing of Stat3 Signaling to Treat Relapsed Disease After Transplantation; Cellular Immunotherapy After Stem Cell Transplantation. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID): Development of Novel Influenza Antivirals; Methods of Clinical Sample Preparation for Rapid Detection of Bacterial Pathogens; Inhaled Delivery of Clofazimine (CFZ) - An Important Anti-tuberculosis Drug; Simple, Inexpensive Unit for Removing Cells from Small Amounts of Blood in Resource-Limited Settings. NATIONAL INSTITUTE ON DRUG ABUSE (NIDA): Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) - CENTER FOR GLOBAL HEALTH (GCH): Diagnostic Tools to Support the Elimination and Control of Neglected Tropical Diseases. NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION (NCCDPHP): Optical Character Recognition Software for Scanning Nutrition Facts Panel. NATIONAL CENTER FOR EMERGING ZOONOTIC AND INFECTIOUS DISEASES (NCEZID): Development of Nanoparticle Dengue Diagnostic Tests. NATIONAL CENTER FOR HIV/AIDs, VIRAL HEPATITIS, STD, AND TB PREVENTION (NCHHSTP): Yeast-derived Candidate of Hepatitis E Virus Vaccine; Multiplex Assay for Simultaneous Detection of Hepatitis and Other Viruses; Improved Antibody Preparation for Post-Exposure Prophylaxis Against Hepatitis A. NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES (NCIRD): Thermostable Dry Vaccine Formulation for Microneedle Administration; Thermostable Oral Vaccines to Combat Enteric Diseases.


2. NIH/CDC SBIR Contract Solicitation PHS 2015-1, including proposal forms, will be available electronically on/around August 15, 2014 through the NIH Small Business Research Funding Opportunities Web site and at fedbizopps.gov. (Note: The PHS 2014-2 Omnibus Solicitation of the National Institutes of Health, Centers for Disease Control and Prevention, Food and Drug Administration, and Administration for Children and Families for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) GRANT Applications, where investigator-initiated ideas are encouraged, is still open and is available at the same Web site noted above with a remaining due date of December 5, 2014.) To understand better the differences between grants and contracts, see Contracts vs. Grants: What's the difference? (http://grants.nih.gov/grants/funding/contracts_vs_grants.htm) LINKURL: http://grants.nih.gov/grants/funding/sbir.htm LINKDESC: National Institutes of Health Small Business (SBIR/STTR) Research Funding Opportunities. E-mail: sbir@od.nih.gov
Added: Aug 15, 2014 2:56 pm

Points of Contact:

Office of Extramural Programs, Office of Extramural Research, National
Institutes of Health, Phone 301-435-2688, sbir@od.nih.gov.

Contracting Office Address:

Office of Acquisitions
5601 Fishers Lane, Suite 300, MSC 9821
Bethesda, Maryland 20892-9821

Primary Point of Contact:

Office of Extramural Programs, Office of Extramural Research,
National Institutes of Healthsbir@od.nih.gov
Phone: 301-435-2688
Please consult the list of document viewers if you cannot open a file.

Solicitation 1

Type:
Solicitation
Posted Date:
August 15, 2014
PHS2015-1.pdf (944.13 Kb)
Description: U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS), THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) SMALL BUSINESS INNOVATIVE RESEARCH (SBIR) PROGRAM

PROGRAM SOLICITATION PHS 2015-1

Amendment 1

Type:
Mod/Amendment
Posted Date:
September 11, 2014
Description: PHS 2015-1, Amendment 1 - The purpose of this amendment is to provide corrections and revisions to Sections 3.1, 3.2, 6.4, 8.3, 9, 10, and 12 of the subject solicitation.
Description: Attachment: PHS 2015-1 - Amendment One

Amendment 2

Type:
Mod/Amendment
Posted Date:
October 17, 2014
Amendment_No._2.pdf (160.82 Kb)
Description: The purpose of this amendment is to provide revisions to Section 12 of the subject solicitation and to respond to questions.
:
Office of Acquisitions
6700 B Rockledge Room 3214 MSC7612
Bethesda, Maryland 20892-7612
:
Tiffany Chadwick,
Contract Specialist
Phone: 301-435-0699
:
George Kennedy,
Contracting Officer
Phone: 301-451-2607

Amendment No. 6 to Solicitation for proposals to award a Concession Contract operating overnight accommodations, food and beverage, retail service, fuel and auto services, and other related services within Yosemite National Park

Solicitation Number: YOSE004-16
Agency: Department of the Interior
Office: National Park Service
Location: NPS - All Offices
  • Print
:
YOSE004-16
:
Presolicitation
:
Added: May 05, 2014 6:17 pm Modified: Oct 17, 2014 9:00 pmTrack Changes
The National Park Service (NPS) has issued Amendment No. 6 to the Solicitation of YOSE004-16. This Amendment No. 6 extends the solicitation date to Thursday, January 8, 2015. The Service is working through questions and answers related to the Prospectus and additional time is necessary to ensure interested parties can incorporate any changes resulting from the questions into their proposals.

Any proposal, including that of the existing Concessioner, must be received by the National Park Service, Commercial Services, Attn: Kimberley Gagliolo, 333 Bush Street, Suite 500, San Francisco, California 94104, on Thursday, January 8, 2015, no later than 4:00 p.m. (Pacific Time) in order to be evaluated and considered for award of a Concession Contract.

A hard copy of the Prospectus package is available by contacting Kimberley Gagliolo, Commercial Services Specialist, Pacific West Region, via email to kim_gagliolo@nps.gov or by phone at (415) 623-2227. There is a printing cost recovery charge of $50 per copy to be delivered via Federal Express or $40 if picked up in person. Checks or money orders (no cash or credit cards accepted) must be payable to the National Park Service. You must include a business address (no post office box) to receive a Federal Express package. The Prospectus is also available online at the following website: http://concessions.nps.gov/index.htm. If you choose to retrieve a copy of the Prospectus from the NPS website, please notify Kimberley Gagliolo so you are placed on the mailing list to receive notifications of any future modifications or other correspondence.
Please consult the list of document viewers if you cannot open a file.

YOSE004-16 Amendment No. 1

Type:
Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Posted Date:
August 29, 2014
Description: Questions and Answers
Description: Amendment No. 1
Description: Appendix U (Food and Beverage Drawings)

Amendment 1

Type:
Mod/Amendment
Posted Date:
September 15, 2014
Description: Questions and Answers No. 2
Description: Amendment No. 2
Description: Appendix V Comparable Properties
Description: Appendix W YOSE IPM Plan
Description: Exhibit B-1 Opening Closing Schedule and Operating Hours (Updated)

YOSE004-16 Amendment No. 3

Type:
Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Posted Date:
September 25, 2014
Description: Questions and Answers No. 3
Description: Amendment No. 3
Description: Exhibit B-1 Opening Closing Schedule and Operating Hours (Updated)
Description: Exhibit H-1 Annual Work Plan TM.WA.YL Additions
Description: Exhibit H-1 Annual Work Plan (excel)
Description: Appendix X (Other Drawings)

YOSE004-16 Amendment No. 4

Type:
Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Posted Date:
October 2, 2014
Description: Questions and Answers No. 4
Description: Amendment No. 4
Description: Exhibit D Assigned Land Maps (Updated)
Description: Appendix Y Concession Facilities Info
Description: Appendix Z Equipment
Description: Appendix AA Additional Rates

YOSE004-16 Amendment No. 5

Type:
Other (Draft RFPs/RFIs, Responses to Questions, etc..)
Posted Date:
October 7, 2014
Description: Questions and Answers No. 5
Description: Amendment No. 5
:
12795 West Alameda Parkway
Post Office Box 25287
Denver, Colorado 80225-0287
:
Yosemite National Park and El Portal Administrative Site
Mariposa County
California 95389
United States
:
Kimberley Gagliolo,
Commercial Services Specialist
Phone: (415) 623-2227

THE MAN WHO MADE EBOLA FOR OBAMA IN 2009


FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research
now for free  

Jonathan Towner

Register for free to view:

Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the research activity
of experts around the globe

Geonetwork of Jonathan Towner (preview)

  • Cities where this author has publications
  • Cities where co-authors of this author have publications
Flash Player Required

All Publications



CDC Scientists Identify Presence of Marburg Virus in African Fruit Bats

Published: August 23, 2007
Photo: Sabrina Harper, Dominique Wilkins, Quanza Brooks-Griffin, Maurice Madden
CDC Researchers find possible animal source for Marburg virus. (Photo by WHO)
Scientists at the Centers for Disease Control and Prevention and their collaborators have announced that they have successfully identified the presence of Marburg virus in a common species of African fruit bat (R. aegyptiacus). The scientific publication, released on Wednesday, August 22, in the open-access journal PLoS ONE (www.plosone.org), describes an investigation in the Central African countries of Gabon and Democratic Republic of Congo.
Marburg hemorrhagic fever is a severe and highly fatal disease caused by a virus from the same family as the one that causes Ebola hemorrhagic fever. Both diseases are rare, but can cause dramatic outbreaks with high fatality. There is currently no specific treatment or vaccine.
The natural reservoir for Marburg virus has been the cause of much speculation and scientific investigation. Bats have been suspected of carrying the virus, but until now, virus infection in bats had not been documented. It is also the first study to document the existence of Marburg virus in the Central African country of Gabon.
Photo: Dr. Brian Amman  Photo: Jonathan Towner
Left: Dr. Brian Amman, medical ecologist for the CDC Special Pathogens Branch. Right: Dr. Jonathan Towner, lead author of the publication, shown here testing bats for the presence of Marburg virus infection. (Photos by WHO)
This paper coincides with an ongoing investigation of Marburg infection among miners in a lead and gold mine in Uganda. The mine, located about 300km from Uganda’s capital, Kampala, provides dwelling for at least two bat species. One is the African fruit bat (R. aegyptiacus), identified in the publication as a potential Marburg carrier.
CDC deployed a six-person team to Uganda in early August to join colleagues from the National Institute of Communicable Diseases (NICD) in South Africa, and the World Health Organization, to investigate the source of the Marburg infection. The team has also been conducting studies to determine if other bat species might also carry the virus.
To learn more about Marburg virus please visit: Marburg Hemorrhagic Fever.
Page last updated: August 23, 2007
Content source: Centers for Disease Control and Prevention
Safer, Healthier People
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, U.S.A.
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and